Skip to main content

Government News

academics

 

Clinical research courses

  • NPPA asks companies to reduce prices of anti-cancer medicines

    National pharmaceuticals pricing authority asked pharmaceutical industries to reduce prices of anticancer medicines post declining custom duty to zero. The government reduced custom duty on three Anti-cancer medicines namely, Trastuzumab Deruxtecan, Osimertinib and Durvalumab.

  • Government allows cough syrup export without testing for top market

    The manufacturers are exporting the Cough Syrup to USA, UK, Canada, EU, Japan, Australia, Singapore, Republic of Korea and Switzerland, the requirement of testing from the laboratories may be waived off, in view of approval granted by these countries regulatory agencies for plants or section engaged in manufacturing and export of Cough Syrup, said in a notification by DGFT.

  • Union Health Minister Unveils Key Initiatives to boost Nutrition Support for TB Patients and their Families
    Underscoring Indias resolute commitment to end TB, Shri Nadda announced that Nutrition support under Ni-Kshay Poshan Yojana NPY has been increased from existing Rs. 500 per month, patient to Rs. 1,000/month, patient for entire duration of the treatment.
  • CDSCO under Ministry of Health & Family Welfare becomes Affiliate Member of the International Medical Device Regulators Forum

    The Ministry of Health and Family Welfare has introduced comprehensive regulations for medical devices aimed at aligning the country's regulatory framework with globally accepted standards. This initiative seeks to foster a regulatory ecosystem that promotes growth and innovation in the medical device sector.

  • Top brands of paracetamol, pantoprazole, amoxycilin amongst failed sample, says CDSCO

    CDSCO reported top brands of paracetamol, pantoprazole, amoxicillin and other amongst failed samples reported by CDSCO. These samples are reported to be not of standard quality. Total 59 different brands from well known pharmaceutical industries failed to compile with standard quality.

    Top brands like Clavam 625, Mexclav 625, Shelcal, Pan D failed various assays and quality tests, which were collected and tested by different Drugs Testing Laboratories.

  • Cabinet approves Bio-RIDE scheme to support cutting edge research and development in Biotechnology
    The Union Cabinet, chaired by the Prime Minister Shri Narendra Modi, approved continuation of the two umbrella schemes of Department of Biotechnology , merged as one scheme-‘Biotechnology Research Innovation and Entrepreneurship Development with a new component namely Biomanufacturing and Biofoundry.
  • Now Graduation mandatory for recruitment as CGHS Pharmacist
    ​The Central Government has released new rules for the recruitment of pharmacists in the Central Government Health Scheme, CGHS. According to the new recruitment rules published in the Government of India Gazette Notification, the minimum educational qualification for recruitment to the post of pharmacist in CGHS has been set to a graduation degree.
  • Union Health Minister JP Nadda inaugurates First Policy Makers Forum in New Delhi

    Union Minister of Health and Family Welfare & Chemicals and Fertilizers, Shri J.P. Nadda inaugurated the ‘First Policy Makers’ Forum’, here today, which will run until 22nd August 2024. To elevate India's position in the global pharmaceutical sector, the Indian Pharmacopoeia Commission (IPC), in collaboration with the Ministry of Health & Family Welfare and the Ministry of External Affairs, hosted an international delegation of policymakers and drug regulators from 15 countries.

  • India waives local clinical trials for rare drugs approved in Tier-I countries

    Central Government waives local clinical trials for rare drugs approved in Tier-I countries including USA, UK, Japan, Australia, Canada and EU.

  • Action is taken against companies found selling formulations at prices higher than the permissible price
    As per the provisions of Drugs Order, 2013 , formulations listed in Schedule-I of the DPCO are defined as scheduled formulation under section 2(1)(zb) of DPCO, 2013. Formulations not included in Schedule –I are defined under Para of DPCO, 2013 as non-scheduled formulation. Thus, both schedule and non-schedule drugs are covered under DPCO, 2013.
Subscribe to Government News